Nuwellis Achieves First QUELIMMUNE™ Sale, Cautions Investors
Company Announcements

Nuwellis Achieves First QUELIMMUNE™ Sale, Cautions Investors

Nuwellis (NUWE) has provided an update.

Nuwellis, Inc. has marked a significant milestone with its inaugural commercial sale of QUELIMMUNE™ Therapy to Cincinnati Children’s Hospital, a promising treatment for pediatric patients afflicted by severe immune system-induced inflammation. This achievement comes as part of the company’s exclusive distribution agreement in the U.S. with the therapy’s developer, SeaStar. While this news offers potential growth opportunities for Nuwellis, the company cautions investors against relying solely on forward-looking statements due to the inherent uncertainties of the market and regulatory environment.

Find detailed analytics on NUWE stock on TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskNuwellis, Inc. Reports Strong Q3 Financial Performance
TheFlyMorning Movers: Cigna climbs after confirming not pursuing Humana deal
TheFlyNuwellis reports Q3 EPS $1.74 vs ($63.27) last year
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App